Pacific Shuanglin Bio-pharmacy , Ltd. EBIT

Pacific Shuanglin Bio-pharmacy , Ltd. (000403.SZ) currently reports a EBIT of $340M as of June 2026. That compares with $710M in the prior-year period — down 52.3% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Pacific Shuanglin Bio-pharmacy , Ltd.'s EBIT history and peer comparisons.

Pacific Shuanglin Bio-pharmacy , Ltd.'s EBIT decreased from $710M to $340M — a 52.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pacific Shuanglin Bio-pharmacy , Ltd.'s EBIT of $340M is lower than the Healthcare sector average of $110B. That is roughly 99.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Pacific Shuanglin Bio-pharmacy , Ltd. reported $340M in EBIT as of June 2026. That compares with $710M in the prior-year period — down 52.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $340M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Pacific Shuanglin Bio-pharmacy , Ltd., and consider following 000403.SZ for alerts when major investors trade the stock.